[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554045":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":23,"locations":23,"responsibleParty":24,"collaborators":23,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":23,"eligibilityCriteria":34,"healthyVolunteers":35,"sex":36,"minAge":37,"maxAge":23,"enrollmentInfo":38,"targetDuration":23,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":23,"overallStatus":47,"whyStopped":23,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":23},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cases of aplastic anemia recieving Eltrombopag","EXPERIMENTAL","Newely diagnosed bone marrow aplasia starting treatment with Eltrombopag in adose of 50-150mg \u002F day",[13],"Drug: Eltrombopag",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Eltrombopag","Treatment with eltrombopag in a dose of (50-150mg\u002Fd)",[9],[21,22],"Revolade","Versapenia",null,{"type":25,"investigatorFullName":26,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Noha Mahmoud","Long term outcomes of eltrombopag in patients with bone marrow aplasia, Assiut university hospital insight.","100554045","phase-3-outcomes-in-bone-marrow-aplasia-100554045",false,"NCT06493981","Outcomes in Bone Marrow Aplasia.","Long Term Outcomes of Eltrombopag in Patients With Bone Marrow Aplasia, Assiut University Hospital Insight.","Inclusion Criteria:\n\n\\- Age \\> 18. Newely diagnosed bone marrow aplasia Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients started CSA plus Eltrombopag therapy Normal cardiac, hepatic \\& renal functions\n\nExclusion Criteria:\n\nHypersensitivity or contraindications to eltrombopag. Cardiovascular, pulmonary, hepatic, or renal diseases. History of malignancy. Pregnant, breastfeeding. Inherited bone marrow aplasia. Secondry bone marrow aplasia Previous thromboembolic events. Previous malignancies either solid or hematologic.\n\n\\-",true,"ALL","18 Years",{"count":39,"type":40},3,"ESTIMATED","INTERVENTIONAL",[43],"PHASE3","Bone marrow aplasia, also known as aplastic anemia (AA) is a potentially fatal bone marrow failure syndrome characterized by a paucity of hematopoietic stem cells (HSCs) and progenitor cells with varying degrees of cytopenia and fatty infiltration of the bone marrow space. Underlying mechanisms include immune-mediated attack, telomere defects, and inherent HSC compartment insufficiency. These events may occur individually or in concert, mostly involving effector T cells Historical treatment has included the use of high-dose chemotherapy and allogeneic stem cell transplantation as well as lymphotoxic immunosuppressive therapy (IST) Thrombopoietin (TPO) regulates platelet production, maturation, and release through binding of c-mpl on megakaryocytes.",[46],"Aplastic Anemia Idiopathic","NOT_YET_RECRUITING","2024-07-02",{"date":50,"type":51},"2024-07-10","ACTUAL",{"date":53,"type":40},"2024-07",{"date":55,"type":40},"2030-07",{"name":5,"class":6}]